DC-based cancer vaccines

Research output: Contribution to journalArticle

431 Citations (Scopus)

Abstract

Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with their own DCs loaded ex vivo with tumor antigens. The underlying premise of this approach is that the efficiency and control over the vaccination process provided by ex vivo manipulation of the DCs generates an optimally potent APC and a superior method for stimulating antitumor immunity in vivo compared with the more conventional direct vaccination methods, offsetting the added cost and complexity associated with this form of customized cell therapy.

Original languageEnglish
Pages (from-to)1195-1203
Number of pages9
JournalJournal of Clinical Investigation
Volume117
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Cancer Vaccines
Vaccination
Immunity
Neoplasms
Neoplasm Antigens
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DC-based cancer vaccines. / Gilboa, Eli.

In: Journal of Clinical Investigation, Vol. 117, No. 5, 01.05.2007, p. 1195-1203.

Research output: Contribution to journalArticle

Gilboa, Eli. / DC-based cancer vaccines. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 5. pp. 1195-1203.
@article{b479db52f9664953a6180457c0c99169,
title = "DC-based cancer vaccines",
abstract = "Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with their own DCs loaded ex vivo with tumor antigens. The underlying premise of this approach is that the efficiency and control over the vaccination process provided by ex vivo manipulation of the DCs generates an optimally potent APC and a superior method for stimulating antitumor immunity in vivo compared with the more conventional direct vaccination methods, offsetting the added cost and complexity associated with this form of customized cell therapy.",
author = "Eli Gilboa",
year = "2007",
month = "5",
day = "1",
doi = "10.1172/JCI31205",
language = "English",
volume = "117",
pages = "1195--1203",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - DC-based cancer vaccines

AU - Gilboa, Eli

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with their own DCs loaded ex vivo with tumor antigens. The underlying premise of this approach is that the efficiency and control over the vaccination process provided by ex vivo manipulation of the DCs generates an optimally potent APC and a superior method for stimulating antitumor immunity in vivo compared with the more conventional direct vaccination methods, offsetting the added cost and complexity associated with this form of customized cell therapy.

AB - Because of the large preexisting antigenic load and immunosuppressive environment within a tumor, inducing therapeutically useful antitumor immunity in cancer patients requires the development of powerful vaccination protocols. An approach gaining increasing popularity in the tumor vaccine field is to immunize cancer patients with their own DCs loaded ex vivo with tumor antigens. The underlying premise of this approach is that the efficiency and control over the vaccination process provided by ex vivo manipulation of the DCs generates an optimally potent APC and a superior method for stimulating antitumor immunity in vivo compared with the more conventional direct vaccination methods, offsetting the added cost and complexity associated with this form of customized cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=34248204110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248204110&partnerID=8YFLogxK

U2 - 10.1172/JCI31205

DO - 10.1172/JCI31205

M3 - Article

C2 - 17476349

AN - SCOPUS:34248204110

VL - 117

SP - 1195

EP - 1203

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -